Guggenheim says this little-known cancer stock can more than double from here

Guggenheim initiated coverage of CG Oncology (CGON) with a Buy rating and a $90 price target, projecting a 137% upside from its recent close of $38. The investment firm cited CGON's strong position in the non-muscle invasive bladder cancer (NMIBC) market, highlighting its oncolytic immunotherapy, cretostimogene, for its best-in-class efficacy, durability, and safety, ahead of an anticipated FDA review next year. The analyst noted the NMIBC market's pricing power and long treatment durations, with all 12 analysts covering CGON currently holding a buy or strong buy rating, anticipating a robust catalyst path over the next two years.

Analysis

Shares of CG Oncology could soar from here, according to Guggenheim. The investment firm initiated coverage of the biopharma stock with a buy rating and $90 price target, which implies shares could surge 137% from their Tuesday close of $38. CG Oncology focuses on developing treatments for bladder cancer. The stock has popped 33% in 2025, outpacing the S & P 500's 14% during that time. Guggenheim analyst Brad Canino pointed to the company's solid position within the non-muscle invasive bladder cancer industry. He also applauded CG Oncology's development of cretostimogene, an oncolytic immunotherapy. "The nascent NMIBC drug market has lots of patients, industry pricing power, and long treatment durations, which makes the CGON story rise to the top of quality oncology ideas, in our view, given the best-in-class efficacy, durability and safety of cretostimogene, which will enter FDA review next year," he wrote. Canino continued: "These NMIBC patients undergo therapies to prevent invasive operations or bladder removal (cystectomy), which creates motivation to use the most durable product, such as cretostimogene. These patients also have a non-lethal form of cancer and demand a pristine drug safety profile, which we believe cretostimogene provides." The analyst added that CG Oncology offers a "potentially attractive catalyst path." This includes numerous data and regulatory updates across multiple segments into the next two years. Analysts are bullish on the stock, with all 12 of the ones covering it assigning a buy or strong buy rating, LSEG data shows. ( Learn the best 2026 strategies from inside the NYSE with Josh Brown and others at CNBC PRO Live. Tickets and info here . ) Guggenheim initiated coverage on CG Oncology (CGON) with a "Buy" rating and a robust $90 price target, signaling a potential 137% upside from its recent $38 close. This strong endorsement comes after CGON shares have already surged 33% in 2025, significantly outpacing the S&P 500's 14% gain during the same period. This analyst action reflects a strong positive sentiment towards the biopharma's prospects. The bullish outlook is primarily driven by CGON's lead asset, cretostimogene, an oncolytic immunotherapy targeting non-muscle invasive bladder cancer (NMIBC). Analyst Brad Canino highlights the drug's "best-in-class efficacy, durability, and safety," positioning it strongly ahead of its anticipated FDA review next year. The NMIBC market is characterized by a high patient volume, strong industry pricing power, and long treatment durations, further enhancing cretostimogene's commercial appeal, particularly given patient demand for pristine safety profiles in non-lethal conditions. Furthermore, CG Oncology presents a "potentially attractive catalyst path" over the next two years, with several data and regulatory updates expected across its multiple segments. This positive sentiment is widely shared, as all 12 analysts covering CGON currently assign either a "Buy" or "Strong Buy" rating, according to LSEG data, indicating a strong consensus among financial professionals.

Key Decisions for Investors

• Investors should consider CGON's strong analyst consensus and significant price target from Guggenheim as a potential indicator of future upside.
• Monitor the upcoming FDA review of cretostimogene and other regulatory/data updates over the next two years, as these represent key catalysts for stock performance.
• Evaluate the NMIBC market dynamics, including patient need, pricing power, and treatment duration, which underpin the long-term commercial viability of CGON's lead product.